WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybinThese results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybinAfter receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (, showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol use disorder…

Continue Reading

WednesdayAug 31, 2022 9:15 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Set to Capitalize on US Online Gaming Boom

Commercial gaming revenues in the United States reached a record $14.81bn in 2Q22Online gaming operations grew at an even faster pace, rising by 34.3% YoY to all-time high of $1.21 billionRecent studies have found that the online gaming market space within the United States could triple in size over the next five years, growing to $24.3 billion by 2026Golden Matrix Group, which recently won its Mexican gaming permit, looks well positioned to capitalize on the growth of the US online gaming sector through its B2B white-labelling operations Commercial gaming revenue in the United States reached a record $14.81 billion in…

Continue Reading

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”)GBM is an aggressive form of cancer that occurs in the brain or spinal cordIn the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosisCNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical stage biotechnology company…

Continue Reading

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patternsCYBN is leading the industry in developing proprietary psychedelic-based therapeuticsThe company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders and improving…

Continue Reading

FridayAug 26, 2022 9:00 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Scores Big Q3 Win on International Expansion

GMGI sets new bar for quarterly revenue, topping $9 million for first timeThe company currently has a string of 15 consecutive profitable quartersGolden Matrix is growing through international M&A activity and launching gaming products, including a new highly anticipated eSports platform Tech stocks have rallied since the tech-laden Nasdaq hit a nearly two-year low in June. Most of the first half of the year was dominated by geopolitical drama, and international upheaval fueling recession concerns amid spiking inflation. None of that stopped Golden Matrix Group (NASDAQ: GMGI) from having its best revenue quarter ever, spearheaded by horizontal and vertical growth.…

Continue Reading

FridayAug 19, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Sees Lidar’s Uses Expand, Maintaining Accuracy and Safety Above All

US traffic-related fatalities touched a 16-year high in 2021, outstripping other major economies across the WorldThe US Collision Industry Conference has forecast crash rates to decline by as much as 20% by 2030 on the back of widespread ADAS adoptionCepton has pioneered the use of lidar, a key sensor technology, across automotive and smart infrastructure applications. In 2019, the company was the recipient of the single largest ADAS lidar series production award with Koito on the General Motors business Cepton has now seen its lidar technology expand far beyond its initial intended use, ranging from revisioning public venues and commercial buildings…

Continue Reading

WednesdayAug 17, 2022 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Grows its Product Offering; Looks to Reinforce Business Relationships in Mexico with Scheduled CFDI 4.0 Launch

Freight Technologies Inc., often abbreviated as Fr8Tech, has seen the introduction of a unique solutions suite designed to optimize and automate the supply chain process and provide a platform for B2B cross-border shipping in the NAFTA region Hudson Capital Inc. acquired 100% of Freight App, Inc. as a wholly owned subsidiary on February 14, 2022, and Fr8App (a “DBA” for Freight App, Inc.) is not only a DBA name, it is their core marketplace (a service or platform under the Freight Technologies umbrella) (, the company’s flagship product and platform for cross-border shipping, offers a cloud-based marketplace that simplifies the once-complex…

Continue Reading

WednesdayAug 17, 2022 10:00 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Primed for Online Gambling Explosion in U.S.

Since the federal government stepped out of the way with laws, 6 states so far have legal online casino games, with 3 already topping $1.0 billion in annual revenueLas Vegas-based Golden Matrix Group has built a robust platform it customizes and white labels to international casino operators providing access to over 10,000 gamesWell-suited to curate systems for American operators, Golden Matrix has experienced a surge in sales in 2022 from its Asia-Pacific customers Americans have always embraced gambling, but it has only been in the last decade or so that they had any ease of access outside of traveling to…

Continue Reading

TuesdayAug 16, 2022 10:30 am

QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment

This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families.“CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO.Patent covers formulation and preparation of CycloSam in the U.S. QSAM Biosciences (OTCQB: QSAM) has been awarded a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R). Granted by the U.S. Patent & Trademark Office, the patent “protects how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration…

Continue Reading

TuesdayAug 16, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Announces New COO Appointment; Reveals Attendance at J.P. Morgan Auto Conference

Dr. Liqun Han has been appointed as Cepton’s COO, having led the Company’s product development, commercialization, and operations teams over the past several yearsThe announcement marks a momentous year for the Company, with Cepton recently revealing that it had opened an expanded office within the Metro Detroit area to strengthen its engagements with automotive OEMsCepton attended the J.P. Morgan Auto Conference on August 10, 2022, where they hosted a live presentation for potential investors and other interested parties Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, announced that they appointed Dr. Han to the…

Continue Reading

Contact us: (310) 299-1717